Immatics NV Reports Q2 2025 Results: Net Loss Widens to $82.4M, Driven by Lower Revenue and Higher Non-Cash FX Losses
Immatics N.V. reported a Q2 2025 net loss of $82.4 million, significantly widening from $21.1 million a year prior, driven by a revenue drop to $5.5 million from $22.0 million. Increased research and development expenses rose to $52.9 million, alongside higher administrative costs. Cash reserves decreased to $560.5 million. The CFO, Arnd Christ, will transition out by Q1 2026. Future updates on head and neck cancer and NSCLC are expected in late 2025 and 2026, respectively.
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2025. The company’s total revenue for the period was $5.5 million, a significant decline from $22.0 million in the same quarter of the previous year. This decrease in revenue contributed to a net loss of $82.4 million, compared to a net loss of $21.1 million for the same period in 2024. The increased net loss was also impacted by higher unrealized non-cash foreign exchange rate losses. Research and development expenses rose to $52.9 million from $41.3 million a year earlier, driven by costs associated with advancing product candidates in clinical trials. General and administrative expenses also increased to $15.0 million from $11.8 million. Immatics reported cash and cash equivalents totaling $560.5 million as of June 30, 2025, down from $708.5 million as of December 31, 2024. The company attributes this decrease mainly to ongoing research and development activities and unrealized foreign exchange translational losses. Looking ahead, Immatics plans to report updated data focusing on head and neck cancer in the fourth quarter of 2025, with insights into non-small cell lung cancer (NSCLC) expected in 2026. In a corporate development update, the company announced that its Chief Financial Officer, Arnd Christ, will be transitioning out to pursue other opportunities, remaining in his role until the appointment of his successor or the end of the first quarter of 2026 to ensure a smooth transition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001122657-en) on August 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
